Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

Daniela S. Thommen, Jens Schreiner, Philipp Müller, Petra Herzig, Andreas Roller, Anton Belousov, Pablo Umana, Pavel Pisa, Christian Klein, Marina Bacac, Ozana S. Fischer, Wolfgang Moersig, Spasenija Savic Prince, Victor Levitsky, Vaios Karanikas, Didier Lardinois and Alfred Zippelius
Daniela S. Thommen
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
2Laboratory of Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alfred.zippelius@usb.ch daniela.thommen@usb.ch
Jens Schreiner
2Laboratory of Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Müller
2Laboratory of Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petra Herzig
2Laboratory of Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Roller
3Roche Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anton Belousov
3Roche Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Umana
4Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavel Pisa
4Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Klein
4Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Bacac
4Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ozana S. Fischer
5Department of Surgery, University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Moersig
5Department of Surgery, University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spasenija Savic Prince
6Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Levitsky
4Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vaios Karanikas
4Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Lardinois
5Department of Surgery, University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Zippelius
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
2Laboratory of Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alfred.zippelius@usb.ch daniela.thommen@usb.ch
DOI: 10.1158/2326-6066.CIR-15-0097 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Dysfunctional T cells present in malignant lesions are characterized by a sustained and highly diverse expression of inhibitory receptors, also referred to as immune checkpoints. Yet, their relative functional significance in different cancer types remains incompletely understood. In this study, we provide a comprehensive characterization of the diversity and expression patterns of inhibitory receptors on tumor-infiltrating T cells from patients with non–small cell lung cancer. In spite of the large heterogeneity observed in the amount of PD-1, Tim-3, CTLA-4, LAG-3, and BTLA expressed on intratumoral CD8+ T cells from 32 patients, a clear correlation was established between increased expression of these inhibitory coreceptors and progression of the disease. Notably, the latter was accompanied by a progressively impaired capacity of T cells to respond to polyclonal activation. Coexpression of several inhibitory receptors was gradually acquired, with early PD-1 and late LAG-3/BTLA expression. PD-1 blockade was able to restore T-cell function only in a subset of patients. A high percentage of PD-1hi T cells was correlated with poor restoration of T-cell function upon PD-1 blockade. Of note, PD-1hi expression marked a particularly dysfunctional T-cell subset characterized by coexpression of multiple inhibitory receptors and thus may assist in identifying patients likely to respond to inhibitory receptor–specific antibodies. Overall, these data may provide a framework for future personalized T-cell–based therapies aiming at restoration of tumor-infiltrating lymphocyte effector functions. Cancer Immunol Res; 3(12); 1344–55. ©2015 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Immunology Research Online (http://cancerimmunolres.aacrjournals.org/).

  • Received April 10, 2015.
  • Revision received June 9, 2015.
  • Accepted July 1, 2015.
  • ©2015 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Cancer Immunology Research: 3 (12)
December 2015
Volume 3, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S. Thommen, Jens Schreiner, Philipp Müller, Petra Herzig, Andreas Roller, Anton Belousov, Pablo Umana, Pavel Pisa, Christian Klein, Marina Bacac, Ozana S. Fischer, Wolfgang Moersig, Spasenija Savic Prince, Victor Levitsky, Vaios Karanikas, Didier Lardinois and Alfred Zippelius
Cancer Immunol Res December 1 2015 (3) (12) 1344-1355; DOI: 10.1158/2326-6066.CIR-15-0097

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S. Thommen, Jens Schreiner, Philipp Müller, Petra Herzig, Andreas Roller, Anton Belousov, Pablo Umana, Pavel Pisa, Christian Klein, Marina Bacac, Ozana S. Fischer, Wolfgang Moersig, Spasenija Savic Prince, Victor Levitsky, Vaios Karanikas, Didier Lardinois and Alfred Zippelius
Cancer Immunol Res December 1 2015 (3) (12) 1344-1355; DOI: 10.1158/2326-6066.CIR-15-0097
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Nutlin-3a: An Immune-Checkpoint Activator for NK Cells in Neuroblastoma
  • Therapy to Engage, Expand, and Enable Antitumor Responses
  • Dietary Fructose Promotes Resistance to Cancer Immunotherapy
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement